LONDON, November 20, 2018 /PRNewswire/ --
The Greek authorities announced that BIOPROCANN S.A. is the
recipient of the first production license in Greece. The license will allow BIOPROCANN S.A.
to become a cornerstone in medical cannabis production in
Greece, Europe's premium cultivation ground.
(Logo:
https://mma.prnewswire.com/media/787523/BIOPROCANN_Logo.jpg
)
BIOPROCANN will be conducting business from a state-of-the-art
growing facility of 48.000 m2 in Corinth, Greece. From
inception to investment and implementation, the Company is
leveraged to become a premium cannabis cultivator business brand
with an international footprint.
The Company is set to penetrate in the global cannabis market
demand which is increasing exponentially.
The major market opportunities for medical cannabis include:
- A $57 Billion Worldwide
Market
- Continuing major gains of Companies stocks in the US and
Canada
- Rapid global wave towards legalization of medical and
recreational cannabis extending across the US, Europe and Canada
- A surge of giant consumer companies expanding their product
offerings with cannabis infused or generic cannabis products under
their labelling
- A growing list of qualifying conditions and benefits from
medical cannabis
As a premium cannabis cultivator which surpasses quality
assurance requirements, BIOPROCANN S.A. will be the standard for
precision cultivation environment while offering a significant
number of new jobs for the country.
The global cannabis revolution just reached Greece and it is forecasted that these
licenses will play a major role in meeting the rapid increase of
demand for medical cannabis being available for prescription for an
increasing number of medical conditions.
Inundated by market developments, one country after another will
seek to fulfil internal demand with imports. The British
Government has added medical cannabis to the list of medicines
available to patients on the National Health Service as of
November 1st 2018.
In considering the global demand development landscape and
having already structured its operations accordingly, BIOPROCANN
S.A. is geared for rapid production turn out and is also targeting
its business priorities towards the UK and German markets.
ABOUT BIOPROCANN S.A.
BIOPROCANN S.A. was created in 2018 in Greece, in view of the opening of the market
for the cultivation of medical cannabis in the country.
The Company obtained the first license issued by the Greek
Government, having submitted a proposal for a model of precision
cultivation that exceeds international standards to become the
benchmark of the requirements of the domestic and international
market for medical cannabis production.
URL: http://www.bioprocann.gr
E-MAIL: info@bioprocann.gr